A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer

CONCLUSIONS: Afatinib taken orally was safe and well-tolerated up to 280 mg every 7 days in brain cancer patients.PMID:38680990 | PMC:PMC11046985 | DOI:10.1093/noajnl/vdae049

Source: Adv Data - April 29, 2024 Category: Epidemiology Authors: Tiffany M Juarez Jaya M Gill Annie Heng Jose A Carrillo Naveed Wagle Natsuko Nomura Minhdan Nguyen Judy Truong Lucia Dobrawa Walavan Sivakumar Garni Barkhoudarian Daniel F Kelly Santosh Kesari Source Type: research